Shandong Xinhua Pharmaceutical Co., Ltd. (H-share code: 00719) has issued an announcement regarding unusual fluctuations in its A-share trading on the Shenzhen Stock Exchange. The company noted that from September 18, September 21, and September 22, 2026, the closing prices of its A-shares rose cumulatively by 20% over three consecutive trading days, which, according to exchange rules, constitutes abnormal trading activity. Following a thorough review of the circumstances, the company provided the following clarifications.

First, the company confirmed that no corrections or supplements are required for any previously disclosed information. Second, it found no undisclosed material news in recent public media reports that could significantly impact the trading price of its shares. Third, there have been no major changes in the company's recent operational conditions or its internal and external business environment.

On September 21, 2026, the company released several announcements regarding the receipt of drug registration certificates, including one for magnesium sulfate, sodium sulfate, and potassium sulfate oral concentrated solution, one for donepezil hydrochloride orally disintegrating tablets by a subsidiary, and one for levocarnitine oral solution. Earlier, on September 1, 2026, the company had disclosed that azithromycin tablets had passed the consistency evaluation for generic drugs.

The company stated that it has not identified any other material information requiring disclosure that could substantially affect its share price. Additionally, inquiries with its controlling shareholder and actual controller confirmed that there are no undisclosed major matters or plans under consideration concerning the company. Furthermore, a check revealed that neither the controlling shareholder nor the actual controller traded the company's shares during the period of abnormal price fluctuation.